Why asbestos is so dangerous

March 8, 2018, Swiss National Science Foundation
Credit: CC0 Public Domain

The fact that asbestos causes cancer has been largely undisputed for nearly 50 years. Now, researchers supported by the Swiss National Science Foundation (SNSF) have discovered why the fibres cause such damage to the body. "Chronic exposure to asbestos triggers a type of tissue repair," says Emanuela Felley-Bosco, who led the study. "The immune system goes out of balance and is no longer strong enough to combat tumour formation." The research – a collaboration between the University Hospitals of Zurich, Geneva and Toronto (Canada) as well as the University of Fribourg and ETH Zurich – was published in the journal Oncogene.

Micro-injuries lead to cell proliferation

Contrary to popular belief, doesn't cause lung cancer. Rather, it passes through the lungs into a cell layer that surrounds all internal organs (the mesothelium). However, the lymphatic system is unable to clear the long and pointed fibres. Consequently, they remain stuck in the mesothelium where they cause persistent tissue injury, which can lead to cancer. To investigate how organisms react, the researchers injected into the abdominal cavity of mice, which also contains mesothelium tissue.

Although asbestos is chemically harmless, these micro-injuries trigger an : inflammatory signals are sent out, mobilising . Tissue repair signalling pathways are activated in the inflamed mesothelium, which tpromote and thereby favour the growth of tumours. Moreover, the team found an accumulation of mutations in RNA – a kind of working copy of DNA. The researchers hypothesise that, among other things, these mutations serve to attenuate the immune response. As a result, tumour formation is no longer effectively combated and cancer can develop.

A similar mechanism is at work in humans: analysis of data from a gene bank revealed that tumours from patients with poor outcomes also produce large amounts of the enzyme that causes the mutations in the RNA.

Early recognition and immune therapy

"Previously, cancer caused by asbestos was a black box," says Felley-Bosco. Her team's findings will be useful in recognising early signs of inflammation and in developing a specific therapy against mesothelial cancer. "A therapy against immune system inhibitors is a promising approach," says Felley-Bosco. "Similar therapeutic approaches to treating mesothelial cancer are already being used today." A clinical study of immunotherapy at the advanced stage of the disease is also under way at five Swiss hospitals and ten other hospitals in the UK and Spain.

The findings could also prove useful in understanding other types of cancer that can be caused by chronic inflammations such as ulcerative colitis, Crohn's disease and Helicobacter pylori infections.

Explore further: Mesothelial cells promote ovarian cancer metastasis

More information: Hubert Rehrauer et al. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations, Oncogene (2018). DOI: 10.1038/s41388-018-0153-z

Related Stories

Mesothelial cells promote ovarian cancer metastasis

September 9, 2014
Less than half of the women diagnosed with ovarian cancer will survive beyond 5 years. Ovarian cancer readily spreads to abdominal organs, which are covered by a layer of cells called the mesothelium. Ovarian cancer cells ...

Cancer from asbestos caused by more than one cell mutation

December 3, 2014
It has been a long held belief that tumors arising from exposure to asbestos are caused by mutations in one cell, which then produces multiple clones. This hypothesis is challenged by new research published in the open access ...

Team publishes landmark asbestos study

November 2, 2017
A landmark study from The Australian National University (ANU) into the health impacts of living in a house with loose-fill asbestos insulation has been published in the international journal The Lancet Public Health.

Molecular profiling of melanoma tumours explains differences in survival after T cell therapy

November 28, 2017
The more times metastasised melanoma has mutated and the patient's immune system has been activated against the tumour – the better the chances of survival after immunotherapy. This is what emerges from a research collaboration ...

Cancer can be combated with reprogrammed macrophage cells

May 20, 2016
Researchers at Karolinska Institutet have generated antibodies that reprogramme a type of macrophage cell in the tumour, making the immune system better able to recognise and kill tumour cells. The study, which is published ...

A lead candidate for immunotherapy may increase tumour growth in certain cancers

May 12, 2017
Boosting a part of the immune system known to have anti-tumour properties may actually help tumours grow in cancers linked to chronic inflammation.

Recommended for you

Researchers discover new anti-cancer protein

March 21, 2018
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...

Targeting telomeres to overcome therapy resistance in advanced melanoma

March 21, 2018
A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly active telomerase to treat therapy-resistant melanoma. ...

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.